01 Biologic Therapies Are Expanding Into More Dermatological Conditions The need for effective treatments for moderate-to-severe inflammatory skin diseases is expanding the use of biologic therapies across dermatology. FDA approval of Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis in 2024 was supported by three clinical trials involving 1,062 patients, reflecting continued development of targeted biologics for chronic skin conditions. This transition gives dermatologists more pathway-specific treatment options and improves the ability to manage patients who do not respond adequately to topical therapies.
02 Targeted Small-Molecule Therapies Are Increasing Treatment Precision in Dermatology The need for effective treatment with more localized or pathway-specific mechanisms is increasing the adoption of targeted small-molecule therapies in dermatology. FDA approved Anzupgo (delgocitinib) in 2025 for moderate-to-severe chronic hand eczema after two clinical trials involving 960 adults, while JAK and PDE-4 inhibitors provide additional targeted approaches for inflammatory skin conditions. This transition broadens non-biologic treatment
01 Increasing Healthcare Expenditure on Skin Diseases and Expansion of Dermatology Clinics Are Increasing Demand for Dermatological Treatments, Which Drives the Dermatological Therapeutics Market. Increasing healthcare expenditure on skin diseases creates greater capacity for diagnosis, prescription treatment, and long-term disease management. Higher spending by healthcare systems and patients supports procurement of topical medicines, oral therapies, and other dermatological treatments. The outcome is stronger demand for therapeutic products from hospitals, clinics, pharmacies, and dermatology practices. For example, healthcare spending on conditions such as psoriasis, eczema, and acne supports continued use of prescription creams, oral medicines, and maintenance therapies.Expansion of dermatology clinics improves access to specialized diagnosis and treatment for patients with acute and chronic skin conditions. A larger network of clinics increases prescription volumes and creates additional procurement requirements for dermatological medicines and treatment products. The outcome is broader distribution and stronger demand for therapies across both established and emerging markets. For example, dermatology clinics can provide prescription treatments for acne, atopic dermatitis, psoriasis, and other chronic skin disorders.
01 High Costs of Dermatological Treatments and Stringent Regulatory Requirements for New Dermatological Drugs Restrain Market Expansion. High costs of dermatological treatments can limit patient access, particularly for advanced therapies, biologics, and long-term treatment regimens. Expensive medicines, diagnostic procedures, specialist consultations, and repeated treatment cycles can increase the financial burden on patients and healthcare systems. These affordability barriers can reduce treatment uptake and limit the broader adoption of advanced dermatological therapies.Stringent regulatory requirements can increase the time and cost required to develop and commercialize new dermatological drugs. Clinical trials, safety evaluations, efficacy assessments, quality standards, and regulatory documentation can extend development timelines and raise investment requirements. These compliance barriers can delay product launches, discourage smaller developers, and slow the expansion of novel dermatological therapies.
01 Growth of At-Home Dermatology Treatment and Expansion of Digital Dermatology Platforms Are Creating New Commercial Opportunities, Which Offers Growth Opportunities. Patients with chronic skin conditions, dermatology providers, and pharmaceutical companies can use home-based treatment options for conditions that require regular management. At-home therapies create revenue through prescription products, patient-support services, and home-use treatment devices. Companies such as Galderma and Almirall offer dermatological treatments that support home-based care.Patients, dermatologists, telehealth providers, and pharmaceutical companies can use digital platforms for remote consultations, treatment monitoring, and prescription management. Digital services create revenue through consultation fees, platform subscriptions, prescription services, and remote monitoring solutions. Companies such as Ro and Teladoc Health operate digital healthcare platforms that include dermatology services.
01 Slow Adoption of Biosimilars and Alternative Therapies and Difficulty Developing Therapies for Diverse Patient Profiles Hinder Market Growth. Limited physician and patient confidence in biosimilars, along with formulary restrictions and switching requirements, can slow the uptake of lower-cost alternatives and limit competitive market expansion. In the U.S., adalimumab biosimilars accounted for only 27% of total adalimumab prescriptions by May 2025, despite substantially lower prices than the originator.Dermatological diseases show substantial variation in disease severity, genetics, comorbidities, and treatment response across patient groups. This biological diversity makes it difficult for companies to identify consistently effective therapies and can increase clinical-development uncertainty, delaying successful product launches.
June 2026 – AbbVie Acquires Apogee Therapeutics to Strengthen Dermatology PortfolioAbbVie announced the acquisition of Apogee Therapeutics for approximately USD 10.9 billion, significantly strengthening its immunology and dermatology pipeline. The acquisition adds zumilokibart, a long-acting investigational treatment for atopic dermatitis, reinforcing AbbVie's position in inflammatory skin disease therapeutics.
May 2026 – Galderma Expands Nemolizumab Rollout for Chronic Skin DiseasesGalderma expanded the commercialization of Nemluvio (nemolizumab) across additional markets following regulatory approvals. The biologic targets prurigo nodularis and atopic dermatitis, expanding Galderma's dermatological therapeutics portfolio for chronic inflammatory skin conditions.
March 2026 – Eli Lilly Advances Late-Stage Dermatology PipelineEli Lilly and Company continued advancing clinical development of novel immunology therapies for dermatological disorders, including investigational biologics for atopic dermatitis and other inflammatory skin diseases, strengthening its specialty dermatology pipeline.
February 2026 – Johnson & Johnson Expands Dermatology Immunology ResearchJohnson & Johnson Innovative Medicine expanded research and development activities focused on targeted therapies for immune-mediated skin disorders, supporting next-generation treatment options for patients with chronic dermatological diseases.